Prothena | PRTA - Ordinary Share Capital


Prothena reported $53.83M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Agios Pharmaceuticals USD 58.45M 169K Dec/2025
Akebia Therapeutics USD 265.42M 199K Dec/2025
ALKERMES USD 165.61M 503K Dec/2025
Alnylam Pharmaceuticals USD 132.38M 585K Dec/2025
Amgen USD 539M 1000K Dec/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 192.3M 201K Dec/2025
Exelixis USD 268.1M 2.03M Sep/2025
Immunic USD 8K 4K Jun/2024
Incyte USD 198.46M 2.33M Dec/2025
Ionis Pharmaceuticals USD 161.97M 836K Dec/2025
MacroGenics USD 63.32M 60K Dec/2025
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Prothena USD 53.83M 3K Dec/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 0 Dec/2025
Xoma USD 87K 1000 Jun/2024